The primary purpose of this study is to develop pharmacokinetic population models for the two antiviral drugs, remdesivir and hydroxychloroquine, which are tested for treatment of COVID-19 in the WHO NOR COVID 19 study. The main purpose of the population models will be to use them to individualize the dosage for future use in the treatment of COVID-19. In addition, the exploratory effect and side effects of COVID-19 treatment should be investigated in the measurement of viral decay, persistent inflammation and cardiac and renal function.

More information available at: